- Acura Pharmaceuticals (OTC:ACUR) extends a worldwide license to its IMPEDE abuse-deterrent technology to Bayer Healthcare (OTCPK:BAYRY) for use in an undisclosed methamphetamine-resistant pseudoephedrine-containing product. The companies will jointly develop it for the U.S. market.
- Bayer also has the right to negotiate for a worldwide license to IMPEDE for additional products. Financial terms are not disclosed.
- The IMPEDE technology platform is an advanced polymer matrix that is used in Acura's Nexafed. It is designed to limit or disrupt the extraction of pseudoephedrine from tablets.
Acura Pharma inks IMPEDE development deal with Bayer
Recommended For You
About ACUR Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ACUR | - | - |
Acura Pharmaceuticals, Inc. |